Ritchlin CT, et al. Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study. ACR 2018, abstract L17.
Diclofenac verhoogt risico op hartinfarct, naproxen niet
okt 2018 | Myocardinfarct, Spondyloartritis